QoL as measured by the EQ-5D, EQ-5D VAS and KCCQ; all-cause hospitalisation and the need for subsequent procedures (CABG and PCI) showed clinically important benefit from CABG (plus medical management). The outcomes QoL (SF-12) and stroke showed no clinically important effect of CABG (plus medical management). All-cause mortality at 30 days showed a clinically important harm of CABG (plus medical management), while at the extended follow-up period of 9.8 years there was evidence of a Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 clinical benefit of CABG (plus medical management). No evidence was found for the outcome improvement in ejection fraction. The evidence for the outcomes from one study (n=136) comparing an invasive strategy (angiography followed by PCI or CABG at the clinician s discretion) with medical management were all rated as very low. This was due to a risk of bias and imprecision as a result of wide confidence intervals around the effect estimate. Evidence for the outcome all-cause mortality showed a clinically important harm of the invasive strategy (associated with wide confidence intervals around the effect estimate) while evidence for the outcome QoL as measured by the EQ-5D and MLWHF showed no clinically important effect. No evidence was found for improvement in ejection fraction. Economic No relevant economic evaluations were identified. Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 6.3.1.6 Recommendations and link to evidence Recommendations Do not routinely offer coronary revascularisation to people who have heart failure with reduced ejection fraction and coronary artery disease. 